Sign Up Today and Learn More About Applied StemCell Stock
Invest in or calculate the value of your shares in Applied StemCell or other pre-IPO companies through EquityZen's platform.
Applied StemCell Stock
Applied StemCell is a biotechnology company providing animal and cell line models as tools for drug discovery and diagnostics.
About Applied StemCell Stock
Founded
2008
Headquarters
Milpitas, CA, US
Industries
Science and Engineering, Health Care, Biotechnology
Applied StemCell Inc. (ASC) is a fast growing biotechnology company providing animal and cell line models as tools for drug discovery and diagnostics. Using our proprietary TARGATT™ gene modification technology, we make site-specific Knockin mouse, rat and human cell line models fast and efficient for pharmaceutical and academic community. Based on our Proprietary Technologies, we focus on the development and commercialization of: Mouse models (Knockin, Knockout, Transgenic, Site-specific transgenic - TARGATT™, Humanized mouse models) Rat models Human cell line model (Gene modified iPSC - adult stem cell / progenitor cells - differentiated cells) Stem cell culture products (optimized stem cell medium and reporters) Gene engineering in stem cells or other mammalian cells (e.g. generation of protein - production mammalian cell lines) We are striving to improve and expand our technologies and product lines to meet the increasing requirements of biomedical community. ASC welcomes your comments, suggestions and ideas.
Applied StemCell Management
Leadership team at Applied StemCell
Chief Executive Officer, President, and Co-Founder
Ruby Yanru Chen-Tsai
Join now and verify your accreditation status to gain access to:
- Applied StemCell current valuation
- Applied StemCell stock price
- Available deals in Applied StemCell and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in Applied StemCell stock?
Accredited investors can buy pre-IPO stock in companies like Applied StemCell through EquityZen funds. These investments are made available by existing Applied StemCell shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Applied StemCell stock?
Shareholders can sell their Applied StemCell stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
